In the context of the changing drug and device landscape, innovators must
At the same time, the emergence of value-based payment models provides an unprecedented opportunity for companies: They are no longer constrained by payment silos in creating and monetizing truly innovative products.
In this Perspective, the authors discuss the risk that strategic behavior by health insurers could unravel the market for curative therapies for chronic diseases. They present a framework to analyze policy options to remedy this problem.
Medical device innovation has traditionally focused on improving performance, with little regard to cost, but new incentives will force device manufacturers to redirect investments from the spectacular toward the prudent: the end of sexy.
Little is known about the health status of the 7.3 million Americans who enrolled in insurance plans through the Marketplaces established by the Affordable Care Act in 2014.
This paper offers a research-grounded perspective on innovative financing mechanisms to facilitate access to expensive yet highly effective breakthrough medical treatments.
The U.S. Food and Drug Administration is expected to release regulations outlining lower-cost approval requirements for so-called biosimilar drugs. This Perspective combines prior research and recent data to estimate cost savings in the U.S. market.
The authors assess the differential clinical and economic value of fidaxomicin compared with metronidazole and vancomycin in the treatment of Clostridium difficile infection (CDI).
Identifies promising policy options to spur the creation of new medical technologies that will reduce total U.S. health care spending or will provide health benefits that justify any increase in spending.
This report identifies promising policy options to spur the creation of new medical technologies that will reduce total U.S. health care spending or will provide health benefits that justify any increase in spending.
This paper evaluates the causes of the unmet need for investment in drugs targeting central nervous system diseases and discusses policy solutions to better align drug development with untreated disease burden.
Health information technology has not achieved its full potential, but its benefits should grow over time. Because health care is largely regulated at the state level, the states can play a valuable role as laboratories for innovative policies.
The pharmaceutical industry can and should reconfigure its considerable resources to develop innovative and meaningful business models that are based on services that improve access and adherence to prescription drugs for common chronic conditions.
Underuse of controller therapy among Medicaid-enrolled children is common and leads to more emergency department (ED) visits and hospitalizations.
Takes a first step toward developing a policy research agenda for improving access to non-communicable disease medicines in the developing world based on a systematic analysis of obstacles to access and potential solutions.
